Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt (GERD Q NIS)

October 2, 2014 updated by: AstraZeneca
The purpose of this study is to calculate the prevalence of gastroesophageal reflux disease (GERD) by mean of GERD-Q questionnaire in patients with upper gastrointestinal tract symptoms in Egypt.

Study Overview

Status

Completed

Conditions

Detailed Description

Prevalence of Gastroesophageal reflux disease (GERD) in patients with upper gastrointestinal tract symptoms in Egypt

Study Type

Observational

Enrollment (Actual)

3170

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Al MENIA, Egypt
        • Research Site
      • Alex, Egypt
        • Research Site
      • Asuit, Egypt
        • Research Site
      • Aswan, Egypt
        • Research Site
      • Banha, Egypt
        • Research Site
      • Cairo, Egypt
        • Research Site
      • Domiaat, Egypt
        • Research Site
      • Hurghada, Egypt
        • Research Site
      • Ismailia, Egypt
        • Research Site
      • Kafr el-Sheikh, Egypt
        • Research Site
      • Kalubia, Egypt
        • Research Site
      • Luxor, Egypt
        • Research Site
      • Mahala, Egypt
        • Research Site
      • Mansoura, Egypt
        • Research Site
      • Menofia, Egypt
        • Research Site
      • Port-Saeed, Egypt
        • Research Site
      • Qena, Egypt
        • Research Site
      • Sharkiah, Egypt
        • Research Site
      • Sohag, Egypt
        • Research Site
      • Suiz, Egypt
        • Research Site
      • Tanta, Egypt
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Community patients

Description

Inclusion Criteria:

  • 18 years and above
  • Attending the medical office and reporting symptoms suggestive of upper gastrointestinal tract symptoms such as heartburn/regurgitation, abdominal pain, bloating, belching and nausea/vomiting.

Exclusion Criteria:

  • Participating on a clinical trial during the last 3 months.
  • Patients not able to read and/or understand the GERD-Q questionnaire.
  • Patients already included in the study in other participating site.
  • Patients taking PPIs or H2blockers in the l

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients with Gastrointestinal Trackt Symptoms

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of patients scoring ≥ 8 in GERD-Q
Time Frame: baseline

Percentage of patients scoring ≥ 8 in GERD-Q will be considered as suffering from GERD.

The GERD-Q is a potentially useful tool for family practitioners and other health care professionals in diagnosing and managing GERD without initial specialist referral or endoscopy.

The Egyptian-validated version of the GERD-Q will be used for the study purposes.
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Socio-demographic characteristics of patients diagnosed with gastroesophageal reflux disease (GERD)
Time Frame: baseline
Descriptive analysis of socio-demographic characteristics of patients diagnosed with gastroesophageal reflux disease (GERD) in Egypt.
baseline
Treatment patterns in patients diagnosed with gastroesophageal reflux disease (GERD)
Time Frame: baseline
Descriptive analysis of treatment patterns in patients diagnosed with gastroesophageal reflux disease (GERD) in Egypt.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Investigators

  • Study Director: Dina A Ahmed, MD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

July 1, 2014

Study Registration Dates

First Submitted

July 3, 2012

First Submitted That Met QC Criteria

July 9, 2012

First Posted (Estimate)

July 10, 2012

Study Record Updates

Last Update Posted (Estimate)

October 3, 2014

Last Update Submitted That Met QC Criteria

October 2, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-GEG-XXX-2012/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patients With Upper Gastro-intestinal Symptoms

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe